Very strong news for shareholders.

http://www.vitrobiopharma.com/wp-content/uploads/2009/10/fluorescent-msc-10-3.pdf

Yes it is. I am fairly well convinced that something is going on at VODG and hopefully what it is will prove to be of significantly good news to shareholders.

Your hatred for this tiny company blinds you to what is going on here and it makes you look dumb as a dirt bag.

At the very least it could mean at least one new investor so we would have a total of what, 4?

True. That was then. This is now and could be different. I suspect it could mean the end of an era and the beginning of a "new" one. Possibly as meaningful as the sale of the stock was at $4+.

Could this signal an important turning point?

VODG is a great risk/reward investment.

I have changed my opinion over the past few months from this company possibly being a huge high risk home run to being a much lower risk, but very, and the operative word here is VERY substantial investment opportunity. FYI - I ain't a kid, been doing this longer then most folks are old on this site. That said read the entire post if you care.

Several recent trips and visits with various companies brings me to this conclusion. VODG should benefit from the growth in cell immortalization as it supplies an ever growing industry with superb, high tech/quality research product. The sales base will prove to be large and more stable. There will not be the need for FDA approval. There will not be the homerun potential either. But given the capitalization structure of the company and the market ...

I would suggest that VODG represents one of the best risk/reward investments in the industry.

Platform technology might be in the future, but that will be many years down the road and not needed to make this company one of the best potential investments you could consider. I own the stock in a sizable way and have for some time. I also have been following the company for over ten years as I was introduced by a friend of mine when it went from $0.40 to $4.50. Back then it was on hope. Today and over the next year, it could prove to be reality. Then again, it might not. I ain't clairvoyant...

Can you tell us more?

Frankly, I know the market will decide over time and I am not going to waste much time here - because mine is too valuable.

The recent news, in my opinion, is very bullish for VODG. Yea, call me a stupid chick or what ever else you testosterone driven slobs are. But I have my reasons, however lame or estrogen driven I am. Hugs and kisses.

Did you say 60% interest rate per annum on their note???
The cash statement for the last quarter on page F-4 states beginning cash $111,337
ending cash $85,137
So the company has less cash by $26,200.
Also for the quarter sales figures:
$1.57MM vs $2.77MM.
THAT IS A DECLINE OF 43%!
Maybe this is a turn Sparks, but frankly I have NEVER heard of a public company having to pay 60% annual interest. Add to that a decline in cash and a 43% drop in sales,
suggests to me what you see may be the ground,
not a turn.

Let me add these other big picture kind of considerations in followup to my prior post.

Nearly ever other BB stock issues "millions" of shares of stock to fund potential business and pay management substantial incomes.

VODG has never done this.

So, where is the potential payoff to management for over TEN YEARS of blood sweat and tears?

Well, maybe there won't be a payoff and Dr. Musick has spent tons of his own money, worked 24/7 just in an attempt to help benefit mankind.

But, on the other hand, maybe ...

the handwriting is on the wall, or in this case in the comparisons of the SEC filings as has so dutifully been documented on this board. Time will tell.

My intuition tells me this could very well prove to be a superior long term investment!

Here is another thing we learned from our visit that I think could be quite meaningful to shareholders.

I will try to explain this the best I can.

As I understand it, currently, VODG offers its product(s) with "markers". The good news is no other competitor currently is in a position to do so. The bad news is the process is not patentable.

The markers provide researchers the capability of being able to follow where the stem cell goes and how it preforms giving significantly better insight into the cellular processes. In cancer research, for example, it can help determine the capability of being able to target cancer cells and have the knowledge of much more precisely knowing what is going on.

This could be a very positive door opener as VODG moves forward in developing sales.

Stock's action reinforced by a recent visit of a small group of shareholders.
We had a very productive meeting and then got together at a local restaurant to discuss our time and conclusions. The following are our personal conclusions on what was discussed.

Again, please recognize, the following comments are our own conclusions. You may agree or disagree, it frankly doesn't matter to me as it will not change our opinions. The market, in time, will prove who's opinions have value. I have taken my valuable time to write this in an effort to provide you with our personal opinions.

1) VODG is attacking 2 markets that do not need FDA approval with total sales of over $300 million growing at a substantial annual rate. VODG management is quite optimistic about it's potential market share. We decided a scant 10% of the market would prove very profitable to current shareholders.
2) VODG is in a unique position and due to the company's size has the capability of adjusting to changing trends much easier then a larger organization.
3) For the first time since we have known Dr. Musick, what we heard him talking about and actually had a gleam in his eye as he discussed it - has to do with what we would call an "exit strategy". This really was very interesting and a significant change from the past. This opinion was also reinforced by the recent Q and changes in verbage as has been presented here so well by others.
4) For the first time, the discussion of VODG taking their technology into FDA approved platform technology appears to no longer be in the business plan. Rather, "partnering" which has been discussed for years, has taken on a much more defined direction. In my personnal opinion, there are real and meaningful discussions current in progress. These changes have also been disclosed in the recent Q, the timing is based upon our read of what was said and what was not said. That said, we all walked away with the same "intuition" as to what was actually being communicated.

As I have stated in the past. We are long term investors and believe the stock offers incredible risk/reward. Anyone with knowledge of management would understand that this company, somewhat to its detriment (IMO) does not fall into the pump and dump category. I don't plan to sell at $.50, $.60 or whatever as I think in five years or so someone will be paying me stock for my current position.

Let me add this - the small group of visting investors are very seasoned. Some, like myself, have probably been investing longer than most people have been living that post on this board. That said, I have had my share of mistakes. My money is where my mouth is and I will be a buyer on any weakness, even though our current position approaches 5% and will require a filing.

Mav, thanks so much for your reply. I so deeply respect your opinions, knowledge and insight. If I ever need a go-to gay guy who can't find his buttock in an outhouse, you will be my first call.
Insider trading? Again, you gotta be the biggest more on I have ever encountered. Your comment is offensive to me and attacks the integrity of Dr. Musick. YOU presume he will provide me with non-public information and thus impinges this man's character.
Why don't you change you ID to poostain or dimwit?

Mav, would be pleased if you provided me a list of questions for my meeting with management?
Your tremendous knowledge and insight could prove helpful.
email me at:
swjack@comcast.net

SHOULDN'T THIS BE A LIABILITY?
On June 7, 2007, the Company and Ms.Wilhelm executed another amendment to her employment agreement which provides that, the Company will issue her 312,500 shares of common stock of the Company, and on May 10, 2010, cash OR common stock, at the option of the Company, equal to the amount, if any, by which $625,000 exceeds the sum of (i) the market value of these 312,500 shares issued to Ms. Wilhelm on June 7, 2007 which she holds on May 10, 2010, and (ii) the amount of proceeds, if any, she received upon the sale of any of the 312,500 shares. Market value of the shares is to be determined at the discretion of the Compensation Committee of the Board of Directors, if any, and should a Compensation Committee not exist, by the Board of Directors.

MITD appears to be on the hook for $625,000 to Ms. Wilhelm, pays to be one of Mr. Parker's "ladies".

This is a new one to me!
9. Estimates

Preparing the Company’s financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

FINANCIAL STATEMENT ESTIMATES?

60% interest rate?
5. Factoring Agreement for Accounts Receivable

In 2008, the Company terminated the factoring agreement with Northern Healthcare that had been in existence since 2005. The Company paid all monies due under the agreement with proceeds from a term loan with Globank Inc. The note under the term loan began on August 1, 2008 in the amount of $500,000, and is an interest only loan for 2 years with interest payable monthly at the rate of 60% per annum.

Raping shareholders?
Check this out.

NOTE D – RELATED PARTY TRANSACTIONS
The Company and Mr. Parker have entered into an employment agreement for a term of five years commencing June 2006. The employment agreement provides for a base salary of $250,000 (exclusive of housing and expense allowances), with bonuses to be determined annually by the Board of Directors.

$250,000 plus housing AND an expense allowance????

Outrageous!

Will do, along with a tape recorder.

Have a scheduled meeting with management the week of June 8th.
I hope to review current and future prospects in as much detail as possilbe. Will tape meetings.

Let me know if you have any questions.

I am considering raising my position to over 5% of the outstanding.

Do your own research. This is not your typical BB management and therefore stock!!! No P&D here.

The following is my opinion based upon 10 years of following this company.

Press release states:
"The current total market for stem cell research tools is estimated to be about $900 million and is projected to expand at 10 to 20% per year in the near future."

Phase 1 current - 2 years
A very good estimate for VODG would be around 10% of market share within a couple years. Given the growth, the $900 million market, in 2 years - should be over $1,000 million.

If you dig around you will find management's referral to potential sales (once they begin)to be $90+ million in a reasonably short period of time.

Personally, I think you will find that to be conservative.

Valuation of stock?
Sales per share could be over $6.
Margins will knock your socks off.


Phase 2
Using cash flow, seek FDA approval for their platform products. This will begin as soon as practically possible.

Now I understand. You be de gay guy from Indy.
Initially I was hurt, but as The Donald said - this is 2009.
Warm and fuzzy feelings to you and your New Jersey boy!

Oh all knowing gay guy, thank you for gracing us with all your insight and wisedom.

We will miss you, but somehow I don't think you will stand by your word.

Good news Mav!!!

Informed people have told me really good news is coming from VODG and it will be of enormous help to you!!!

No kidding, word has it that VODG has successfully immortalized brain cells. But that isn't all!!!

They have been able to grow entire new brains in rats.

Good news dude!!!

Listen, I think I can get you hooked up to be an initial recipient and I know you won't have a lick of trouble in qualifying! Hey, if that doesn't work maybe they can transplant one from one of the rats. It would definitely be an up tick for you!

Brilliant call Mav.
Dude, I feel sorry for you. Don't you know how stupid you sound? Don't you know everybody else is laughing at you.
You need help. Professional help.

Jersey?
Boy?
You are dumb as dirt.

Great points. Let me add this for clarification.
The business plan calls for revenue generated from non-FDA approved stem cell products to fund FDA applications.

This may take more time, but that has been the model from the beginning and one major reason why outstanding shares are so low!!!

Imagine the upside and where this company COULD be in 5 years!!! Just absolutely HUGE. Personally, I think significant gains are in sight as revenues start and then FDA filings for drug approval begin.

IMO, this stock has one of the best risk reward ratios I have ever seen.

Risk? $0
Reward? double digits

Probabilites of success much better than 50/50.

Obviously, I've made my bet. What about you?

Management's email response to a question I sent via email.

"Sorry for my delayed response-it’s been more hectic than usual here. Induced plurapotent stem cell technology is a method for re-programming adult cells to become embryonic stem cells with regard to totopotentiality, i.e., self-renewal capacity and ability to differentiate into any cell of the body. This has been achieved in animal and human cells but required transfection of foreign genes and viral gene components to result in the proper reprogramming. A highly sought after research goal is to reprogram adult cells (hopefully any adult cell but now restricted to certain adult skin cells) using different methods that don’t require foreign and viral genes which create safety issues for therapeutic applications involving introduction of these cells into humans. The report by the Scripps research group is a first report of achieving this effect without genetic engineering or use of viral vectors. This could be highly significant to this field and will undoubtedly result in other attempts to duplicate this etc to validate these apparently break-through results. So, this could be a major breakthrough if it is reproducible and especially extents to other types of cells besides fibroblasts.

Vitro has both tools to support this type of research and proprietary technology that may allow us to carve out a niche within this developing market. This position was described in a company press release dated April 1, 2009."

1. I find several comments very interesting.
Anybody care to add theirs?

It is nice to see things progressing. At times I wish things would move quicker, but remember that it is a balance between excellent cost control and minimization of shareholder dilution.

One of the positives to this could be a huge move to the upside as the company delivers, grows and expands.

Management does not embrace short term promotion and as far as I know they have no IR firm under contract. Rather, they recognize what they have, what it takes to deliver AND the patience and fortitude to attempt to execute their business plan.

I give them very, very high marks on this. The fact is this stock will move as the business plan is executed. If that happens, this stock will be beyond what any of us can imagine.

Thanks for all you hard work and good efforts!

I'm so glad that something has entertained you big boy!

Some background -

http://www.nature.com/nature/journal/v451/n7180/full/451858a.html

Now, consider that VODG's methodology doesn't have the virual problem do to the mechanisms used for introducing the DNA.

My people think this could be very big and seals the deal.

Huge - if you didn't see this, take a look:

GOLDEN, Colo.--(BUSINESS WIRE)-- Vitro Diagnostics, Inc. (VODG:$0.15,00$0.01,007.14%) , dba Vitro Biopharma, announced the introduction of “Tools for Stem Cell and Drug Development™” at the recently held Society of Toxicology meeting in Baltimore, MD. These products are designed to support stem cell and cancer research specifically targeting mesenchymal stem cells (MSCs) and a new type of stem cell called induced plurapotent stem cells (iPS). MSCs are adult stem cells that differentiate into several tissue-specific cells, such as collagen, bone and fat cells as well as others. Expanded usage of adult stem cells such as those provided by Vitro provides two major benefits. First, use of Vitro’s adult stem cells eliminates ethical and religious issues associated with embryonic stem cells. Secondly, the use of Vitro’s adult stem cells will enable use of personalized cells that should eliminate immune rejection of transplanted cells. Also, use of personalized stem cells may lead to a new era of regenerative medicine involving the banking of cells such as umbilical cord blood for later use to generate “designer” stem cells derived from the individual patient for treatment of degenerative disorders including diabetes, heart disease, Alzheimer’s disease as well as cancer and many other disorders.
The recently developed technique of reprogramming adult cells into stem cells may provide the benefits of embryonic stem cells without requiring the sacrifice of embryos. Enhanced expression of certain genes in adult skin cells results in cells called iPS that resemble embryonic stem cells with regard to the capacity to differentiate into any cell type. However, current methods of iPS generation involve genetic engineering using foreign DNA sequences added to the cells being converted to iPS. This step adds considerable safety risks. Generation of iPS without genetic engineering with foreign material is a desirable scientific break-through. Vitro’s new tools facilitate this break-through research by providing well-defined human cells and related products that may be converted to iPS without using foreign DNA material, thus eliminating a major safety risk of currently utilized iPS methodology.
Vitro’s new products also offer important tools for stem cell therapy of cancer. MSCs migrate to cancer stem cells and this characteristic may be used to carry toxic agents to selectively eradicate cancer stem cells. This process should provide a novel cellular therapy to fight cancer with minimal side-effects. The commercial acceptance of these new research tools is significantly expanded by current actions of the U.S. government decreasing restrictions on embryonic stem cell research. While both MSC and iPS research hold promise for replacing embryonic stem cells, the validation of these alternative approaches must involve comparison to embryonic stem cells. Thus, removal of the barriers to embryonic stem cell research should lead to validation of additional cell therapy approaches utilizing adult cellular sources for stem cells. The stimulus funding now available to U.S. research organizations should create significantly expanded U.S. stem cell research and lead to further demonstration of the validity of stem cell therapy of many difficult-to-treat disorders including many types of cancer and diabetes. The economic stimulus funding for medical research will provide a windfall to current stem cell researchers and allow others to join the field. Vitro’s new development tools provide vital components to further all stem cell research.

Sure. Had a meeting scheduled to see how things were going, meet new people, etc. Planned about a month ago for April, postponed about a week ago.
Struck me as unusual - can't remember any other time this sort of thing has happened, but chalked it up to deadlines...
Then the late K and information contained in it. I am trying to reschedule for sometime in June. My guess would be that it confirms the statement in the K and that there are things going on, that in time, might prove very good for shareholders.

Very interesting:
1. the extent of conversions;
2. the timing of the conversions;
3. a canceled meeting in CO for April.

The debt that has been converted to stock, if memory serves me correctly, was guaranteed by some patents. So...
if correct, then there is more good news here then initially meets the eye!!!

Rule 144 - For those who are interested.
http://www.sec.gov/investor/pubs/rule144.htm

I love your posts Mav. Love to read them and laugh.

Nice call on Matech Mav!

In the face of the worst market in over 70 years, you couldn't even get Matech right!

You stated -
"Prediction: under $.10 in next 2 months. EOM"
Wrong again. Good to see you're maintaining your perfect score!

Really funny thing is that you appear to be to stupid to even be embearassed.

Brilliant. Once again, another great call from the Mav. Brilliant.

On 7/10/2008 you posted:

"As someone who heads up the corporate compliance group for a pharmaceutical company I can tell you that even the mention that they are having meetings with another company can be viewed as a material event and could pose potential problems for them if they told one person and didn't share it with everyone."

If in fact this information about you is true (which I seriously doubt), you should be very concerned about your position as HEADING the corpoate compliance for a pharm co. Chances are if you had that position they've fired your sorry arsh.

Yo, Mav, dude, do yourself a favor and quit em bare assing yourself.